Affiliation:
1. Department of Pharmacy Shahid Sadoughi University of Medical Sciences Yazd Iran
2. School of Applied Sciences University of Brighton Brighton UK
3. Tehran University of Medical Sciences Tehran Iran
4. School of Medicine Alborz University of Medical Sciences Karaj Iran
5. Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
6. School of Nutrition and Food Sciences Tabriz University of Medical Sciences Tabriz Iran
7. Maternal and Childhood Obesity Research Center Urmia University of Medical Sciences Urmia Iran
Abstract
AbstractAlthough several studies have revealed the benefits of purslane on glycemic indices, the results of some studies reject such effect. Therefore, aim of this meta‐analysis of randomized controlled trials (RCTs) was to assess the effects of purslane supplementation on glycemic indices. Scientific international databases as Scopus, Web of Sciences, PubMed, Embase, and the Cochrane library were searched up to December 2022. For net changes in glycemic indices, weighted mean differences (WMDs) were calculated using random‐effects models. Purslane supplementation had a statistically significant reduction in fasting blood glucose [FBG, WMD: −6.37; 95% CI: −9.34, −3.40, p < 0.001]. In addition, purslane did not significant effect on serum levels of insulin [WMD: −0.74; 95% CI: −2.58, 1.10; p = 0.430], homeostasis model assessment for insulin resistance [HOMA‐IR, WMD: −0.25; 95% CI: −0.88, 0.37, p = 0.429], and QUICKI [WMD: −0.01; 95% CI: −0.01, 0.03, p = 0.317] compared with the control group. The results of our meta‐analysis revealed a beneficial effect of purslane supplementation as a tool to decrease FBG levels, but not to HOMA‐IR, insulin, and QUICKI levels. However, future high‐quality, long‐term clinical trials are needed to confirm our results.